Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers

Jabbari, Ali; Nguyen, Nhan; Cerise, Jane E.; Ulerio, Grace; Jong, Annemieke de; Clynes, Raphael; Christiano, Angela M.; Mackay‐Wiggan, Julian

doi:10.1111/exd.13060

Cited by 76 publications

(58 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After eight months of tofacitinib treatment (5 mg twice daily for 2 months followed by 10 mg in the morning and 5 mg at night thereafter), the patient had full regrowth of hair at all body sites [73]. There have been other case reports showing efficacy of tofacitinib treatment [74,75]. Adverse effects of tofacitinib use include increased risk of severe infections including tuberculosis, anemia, neutropenia, headache, and mild nausea [74].…”

Section: Janus Kinase Inhibitorsmentioning

confidence: 99%

Alopecia Areata

Engın¹,

Oba²,

Tüzün³

2017

Hair and Scalp Disorders

View full text Add to dashboard Cite

Alopecia areata is an organ-specific autoimmune disease targeting hair follicles. It causes nonscarring hair loss. The prevalence rate of the disease is approximately 1 in 1000 people worldwide. The condition is most commonly seen as circular areas of hair loss, but it may sometimes be as extensive as to involve the whole scalp or whole body. The complex pathophysiology of alopecia areata involves an autoimmune basis. Association of alopecia areata with other autoimmune diseases, such as thyroiditis and vitiligo, and the good response of patients to immunosuppressive treatment support an autoimmune etiology. Although some poor prognostic signs are defined, the course of the disease is unpredictable and the response to treatment can be variable. To date, there are neither preventive nor curative measures to deal with the condition. First-line therapy for patchy disease is topical and intralesional steroids, whereas extensive disease is conventionally managed with immunotherapy. New treatment agents, such as excimer laser, low-dose recombinant interleukin 2, Janus kinase inhibitors, and simvastatin/ezetimibe, are promising.

show abstract

Section: Janus Kinase Inhibitorsmentioning

confidence: 99%

Alopecia Areata

Engın¹,

Oba²,

Tüzün³

2017

Hair and Scalp Disorders

View full text Add to dashboard Cite

show abstract

“…The possibility of reversal of AA by JAK inhibitors was successfully shown in murine model by blocking IFN-γ and interleukin-2 (IL-2) or IL-15 receptor β and by reducing the accumulation of CD8 + T cells [10,109,110]. Both JAK1 and JAK2 (ruxolitinib, baricitinib) and JAK3 (tofacitinib) inhibitors have been reported to effectively treat AA in various case reports [109][110][111][112].…”

Section: Janus Kinase Inhibitorsmentioning

confidence: 99%

“…Both JAK1 and JAK2 (ruxolitinib, baricitinib) and JAK3 (tofacitinib) inhibitors have been reported to effectively treat AA in various case reports [109][110][111][112].…”

Section: Janus Kinase Inhibitorsmentioning

confidence: 99%

See 1 more Smart Citation

New Modalities in the Treatment of Refractory Alopecia Areata

Kılıç¹

2017

Hair and Scalp Disorders

View full text Add to dashboard Cite

Alopecia areata (AA) is a common and complex T-cell-mediated inflammatory disorder. It may be patchy (localized), involve the entire scalp (alopecia totalis) or entire body (alopecia universalis). Alopecia totalis and universalis are often difficult to treat. Although many therapeutic options currently exist in alopecia areata, none of them are curative or preventive. Besides, none of them are approved by Food and Drug Administration (FDA). The disease unfortunately has an unpredictable course. The factors indicating a poor prognosis are the extent of hair loss at the presentation, long duration of the disease, and ophiasis pattern of hair loss. There are only a few randomized controlled studies conducted on recalcitrant AA. Recent research on immunology of hair follicle and recent developments in immunopathogenesis, together with the shared pathways of the disease with other autoimmune disorders, led investigators to focus on novel therapies that target specific immunological pathways. Herein, we will review shortly the current treatment options in recalcitrant alopecia areata based on recently published studies and then will focus on the recently developed broad-spectrum and targeted therapeutics.

show abstract

“…(6) We report a case of significant hair regrowth following treatment with oral tofacitinib citrate for alopecia universalis.…”

mentioning

confidence: 96%